Trial Outcomes & Findings for DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) (NCT NCT04276415)

NCT ID: NCT04276415

Last Updated: 2024-02-15

Results Overview

For hematologic toxicities, a DLT is defined as: Grade (Gr) 4 neutrophil count decreased lasting \>7 days, Gr ≥3 febrile neutropenia, Gr ≥3 anemia requiring transfusion, Gr 4 anemia, Gr 4 platelet count decreased, Gr ≥3 platelet count decreased lasting \>7 days or associated with clinically significant hemorrhage and/or requiring transfusion, and Gr 4 lymphocyte count decreased lasting ≥14 days. For non-hematologic, non-hepatic major organ toxicities, a DLT is all TEAEs of Gr ≥3 except: Gr 3 fatigue lasting \<7 days, Gr 3 nausea, vomiting, diarrhea, or anorexia that has resolved to Gr ≤2 within 3 days with maximal medical management, Gr 3 isolated lab findings not associated with signs or symptoms including alkaline phosphatase increased, hyperuricemia, serum amylase increased, and lipase increased, and Gr 3 hyponatremia lasting \<72 hours developed from Gr 1 at baseline. Symptomatic Gr 4 events were considered DLTs unless there was evidence it was associated with disease progression.

• Recruitment status: TERMINATED
• Study phase: PHASE1
• Target enrollment: 34 participants
• Primary outcome timeframe: Cycle 1 Day 1 to Day 21 (each cycle is 21 days)
• Results posted on: 2024-02-15

Participant Flow

A total of 34 participants who met all inclusion and no exclusion criteria were enrolled and received treatment at 5 clinic sites in the United States and Japan.

Dose Escalation (Part 1) was designed to establish the maximum tolerated dose and recommended dose of expansion (RDE) for DS-6157a. Dose-Expansion (Part 2) was expected to start at the RDE to further characterize the safety and tolerability, pharmacokinetics profile, and efficacy of DS-6157a; however, due to lower than anticipated efficacy in Part 1, the Sponsor decided to terminate the study prior to Dose Expansion. Efficacy analyses were limited in Part 1; no analyses in Part 2 were conducted.

Participant milestones

Measure	Dose Escalation: DS-6157a 1.6 mg/kg Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Overall Study STARTED	4	4	5	13	6	2
Overall Study COMPLETED	0	0	0	0	0	0
Overall Study NOT COMPLETED	4	4	5	13	6	2

Reasons for withdrawal

Measure	Dose Escalation: DS-6157a 1.6 mg/kg Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Overall Study Adverse Event	0	0	0	3	0	0
Overall Study Clinical progression	1	1	0	0	1	0
Overall Study Other	0	0	0	1	0	0
Overall Study Physician Decision	0	0	1	3	2	0
Overall Study Progressive disease	3	3	4	5	1	2
Overall Study Withdrawal by patient	0	0	0	1	2	0

Baseline Characteristics

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

Baseline characteristics by cohort

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.	Total n=34 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	11 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	23 Participants n=8 Participants
Age, Categorical >=65 years	2 Participants n=5 Participants	3 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	0 Participants n=8 Participants	11 Participants n=8 Participants
Age, Continuous	57.3 years STANDARD_DEVIATION 14.4 • n=5 Participants	62.3 years STANDARD_DEVIATION 17.4 • n=7 Participants	60.8 years STANDARD_DEVIATION 10.3 • n=5 Participants	58.4 years STANDARD_DEVIATION 13.0 • n=4 Participants	55.8 years STANDARD_DEVIATION 12.9 • n=21 Participants	53.0 years STANDARD_DEVIATION 9.9 • n=8 Participants	58.3 years STANDARD_DEVIATION 12.4 • n=8 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=8 Participants	15 Participants n=8 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	7 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=8 Participants	19 Participants n=8 Participants
Race/Ethnicity, Customized American Indian or Alaska Native Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race/Ethnicity, Customized Asian	3 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	7 Participants n=4 Participants	2 Participants n=21 Participants	0 Participants n=8 Participants	16 Participants n=8 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race/Ethnicity, Customized White	0 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	16 Participants n=8 Participants
Race/Ethnicity, Customized Other	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants
Region of Enrollment United States	1 participants n=5 Participants	2 participants n=7 Participants	3 participants n=5 Participants	6 participants n=4 Participants	4 participants n=21 Participants	2 participants n=8 Participants	18 participants n=8 Participants
Region of Enrollment Japan	3 participants n=5 Participants	2 participants n=7 Participants	2 participants n=5 Participants	7 participants n=4 Participants	2 participants n=21 Participants	0 participants n=8 Participants	16 participants n=8 Participants

PRIMARY outcome

Timeframe: Cycle 1 Day 1 to Day 21 (each cycle is 21 days)

Population: Dose-limiting toxicities were assessed in the Dose Limiting Toxicity Evaluable Set.

For hematologic toxicities, a DLT is defined as: Grade (Gr) 4 neutrophil count decreased lasting >7 days, Gr ≥3 febrile neutropenia, Gr ≥3 anemia requiring transfusion, Gr 4 anemia, Gr 4 platelet count decreased, Gr ≥3 platelet count decreased lasting >7 days or associated with clinically significant hemorrhage and/or requiring transfusion, and Gr 4 lymphocyte count decreased lasting ≥14 days. For non-hematologic, non-hepatic major organ toxicities, a DLT is all TEAEs of Gr ≥3 except: Gr 3 fatigue lasting <7 days, Gr 3 nausea, vomiting, diarrhea, or anorexia that has resolved to Gr ≤2 within 3 days with maximal medical management, Gr 3 isolated lab findings not associated with signs or symptoms including alkaline phosphatase increased, hyperuricemia, serum amylase increased, and lipase increased, and Gr 3 hyponatremia lasting <72 hours developed from Gr 1 at baseline. Symptomatic Gr 4 events were considered DLTs unless there was evidence it was associated with disease progression.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=3 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=11 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Number of Participants With Dose-limiting Toxicities (DLT) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants

PRIMARY outcome

Timeframe: Baseline up to 30 days after end of treatment, up to approximately 1 year 10 months post-treatment

Population: Treatment-emergent adverse events (TEAEs) were assessed in the Safety Analysis Set.

Treatment-emergent AEs (TEAEs) are adverse events with an onset date during the on-treatment period. Adverse events will be graded according to NCI CTCAE Version 5.0 and coded using the current version of Medical Dictionary for Regulatory Activities (MedDRA) version 24.1.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Weight decreased	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) White blood cell count decreased	0 Participants	0 Participants	0 Participants	3 Participants	5 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Decreased appetite	3 Participants	2 Participants	4 Participants	6 Participants	4 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Any TEAE	4 Participants	4 Participants	5 Participants	13 Participants	6 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Anemia	3 Participants	2 Participants	4 Participants	6 Participants	3 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Febrile neutropenia	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Neutropenia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Palpitations	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Sinus tachycardia	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Lacrimation increased	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Vitreous floaters	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Abdominal distension	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Abdominal pain	1 Participants	2 Participants	1 Participants	2 Participants	1 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Abdominal pain lower	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Abdominal pain upper	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Anal fissure	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Ascites	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Diarrhea	0 Participants	0 Participants	1 Participants	3 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dyspepsia	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Flatulence	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Gastritis	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Gastrooesophageal reflux disease	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Intestinal perforation	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Nausea	3 Participants	3 Participants	3 Participants	11 Participants	6 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Vomiting	1 Participants	2 Participants	2 Participants	4 Participants	1 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Asthenia	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Chest discomfort	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Fatigue	3 Participants	1 Participants	3 Participants	6 Participants	2 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Malaise	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Mucosal inflammation	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Pyrexia	1 Participants	0 Participants	2 Participants	4 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hepatic function abnormal	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Portal hypertension	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Bronchitis	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Eye infection	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Herpes zoster	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Contusion	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Alanine aminotransferase increased	2 Participants	1 Participants	2 Participants	3 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Aspartate aminotransferase increased	1 Participants	1 Participants	2 Participants	3 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Sleep apnoea syndrome	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Blood albumin decreased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Blood alkaline phosphatase increased	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Blood creatinine increased	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Electrocardiogram QT prolonged	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Neutrophil count decreased	0 Participants	0 Participants	0 Participants	5 Participants	4 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Platelet count decreased	0 Participants	1 Participants	2 Participants	4 Participants	5 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Protein total decreased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dehydration	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperglycaemia	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperuricaemia	0 Participants	1 Participants	1 Participants	1 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypoalbuminaemia	0 Participants	1 Participants	2 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypocalcaemia	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypoglycaemia	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypokalaemia	0 Participants	1 Participants	1 Participants	2 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Arthritis	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Back pain	1 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Flank pain	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Muscle fatigue	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Muscle spasms	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Muscular weakness	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Myalgia	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Disturbance in attention	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dizziness	1 Participants	0 Participants	0 Participants	4 Participants	1 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dysarthria	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dysgeusia	0 Participants	1 Participants	1 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Headache	1 Participants	1 Participants	1 Participants	4 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperaesthesia	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Peripheral sensory neuropathy	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Taste disorder	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Anxiety	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Confusional state	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Delirium	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Haematuria	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Pollakiuria	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Proteinuria	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Renal disorder	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Urinary tract obstruction	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Pelvic pain	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Cough	1 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dyspnoea	0 Participants	0 Participants	0 Participants	3 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dyspnoea exertional	0 Participants	2 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Epistaxis	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hiccups	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Rhinorrhoea	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperhidrosis	1 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Rash maculo-papular	1 Participants	1 Participants	1 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Rash papular	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Skin fissures	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypertension	1 Participants	1 Participants	0 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypotension	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Tachycardia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypothyroidism	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Eye disorder	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Constipation	1 Participants	2 Participants	2 Participants	5 Participants	2 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Haematemesis	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Upper gastrointestinal haemorrhage	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Varices oesophageal	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Influenza like illness	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Injection site reaction	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Oedema peripheral	1 Participants	1 Participants	3 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Portal vein thrombosis	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) COVID-19	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Pneumonia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Upper respiratory tract infection	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Fall	1 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Infusion related reaction	0 Participants	0 Participants	0 Participants	3 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Procedural pain	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Blood potassium decreased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Lymphocyte count decreased	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperkalaemia	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyperphosphataemia	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hyponatraemia	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hypophosphataemia	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Athralgia	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Insomnia	1 Participants	2 Participants	1 Participants	2 Participants	2 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Pulmonary embolism	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Alopecia	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Dry skin	1 Participants	2 Participants	3 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Deep vein thrombosis	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Most Frequently Reported (≥10%) Any Grade Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Hot flush	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	181 day*ug/mL Standard Deviation 18.2	399 day*ug/mL Standard Deviation 178	574 day*ug/mL Standard Deviation 150	776 day*ug/mL Standard Deviation 346	1530 day*ug/mL Standard Deviation 507	2140 day*ug/mL Standard Deviation 351
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	223 day*ug/mL Standard Deviation 76.6	761 day*ug/mL Standard Deviation 47.3	733 day*ug/mL Standard Deviation 425	1520 day*ug/mL Standard Deviation 654	2570 day*ug/mL Standard Deviation 11.9	—
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	176 day*ug/mL Standard Deviation 22.6	425 day*ug/mL Standard Deviation 203	549 day*ug/mL Standard Deviation 111	730 day*ug/mL Standard Deviation 349	1530 day*ug/mL Standard Deviation 495	1980 day*ug/mL Standard Deviation 256
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	218 day*ug/mL Standard Deviation 76.9	731 day*ug/mL Standard Deviation 40.4	676 day*ug/mL Standard Deviation 428	1570 day*ug/mL Standard Deviation 746	2450 day*ug/mL Standard Deviation 217	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	6.85 day*ng/mL Standard Deviation 2.16	19 day*ng/mL Standard Deviation 2.49	20.5 day*ng/mL Standard Deviation 5.53	51.8 day*ng/mL Standard Deviation 23.8	74.8 day*ng/mL Standard Deviation 30.2	111 day*ng/mL Standard Deviation 27.9
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	5.95 day*ng/mL Standard Deviation 0.94	22.3 day*ng/mL Standard Deviation 3.58	22.8 day*ng/mL Standard Deviation 10.4	75.9 day*ng/mL Standard Deviation 55.9	70.6 day*ng/mL Standard Deviation 30.4	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in participants with available data in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=12 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	181 day*ug/mL Standard Deviation 18.3	400 day*ug/mL Standard Deviation 157	512 day*ug/mL Standard Deviation 67.1	821 day*ug/mL Standard Deviation 371	1570 day*ug/mL Standard Deviation 401	1690 day*ug/mL Standard Deviation 499
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	250 day*ug/mL Standard Deviation 36.8	718 day*ug/mL Standard Deviation 35.1	780 day*ug/mL Standard Deviation 342	1430 day*ug/mL Standard Deviation 458	2400 day*ug/mL Standard Deviation 240	—
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	176 day*ug/mL Standard Deviation 22.8	427 day*ug/mL Standard Deviation 182	549 day*ug/mL Standard Deviation 113	781 day*ug/mL Standard Deviation 363	1570 day*ug/mL Standard Deviation 394	1590 day*ug/mL Standard Deviation 388
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	251 day*ug/mL Standard Deviation 31.1	691 day*ug/mL Standard Deviation 24.6	733 day*ug/mL Standard Deviation 344	1460 day*ug/mL Standard Deviation 538	2270 day*ug/mL Standard Deviation 60.8	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in participants with available data in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=12 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	6.48 day*ng/mL Standard Deviation 0.52	21.8 day*ng/mL Standard Deviation 3.86	27.6 day*ng/mL Standard Deviation 5.07	70.7 day*ng/mL Standard Deviation 61.1	66.9 day*ng/mL Standard Deviation 25	—
Pharmacokinetic Analysis: Area Under the Plasma Concentration-time Curve in the Dosing Interval (AUCtau) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	6.85 day*ng/mL Standard Deviation 2.16	19.7 day*ng/mL Standard Deviation 4.01	20.4 day*ng/mL Standard Deviation 5.55	49.5 day*ng/mL Standard Deviation 23.5	69.1 day*ng/mL Standard Deviation 30.7	98.5 day*ng/mL Standard Deviation 18.5

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	2.59 hours Standard Deviation 1.04	2.09 hours Standard Deviation 0.83	2.75 hours Standard Deviation 1.53	2.71 hours Standard Deviation 1.54	2.86 hours Standard Deviation 2.82	2.7 hours Standard Deviation 1.52
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	1.24 hours Standard Deviation 0.99	3.75 hours Standard Deviation 1.23	2.07 hours Standard Deviation 1.65	2.58 hours Standard Deviation 2.48	4.05 hours Standard Deviation 4.71	—
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	1.81 hours Standard Deviation 1.02	4.24 hours Standard Deviation 3.45	2.07 hours Standard Deviation 1.65	4.96 hours Standard Deviation 7.82	2.47 hours Standard Deviation 0.12	—
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	10.5 hours Standard Deviation 8.36	7.26 hours Standard Deviation 2.62	11.1 hours Standard Deviation 8.96	8.42 hours Standard Deviation 7.16	34.17 hours Standard Deviation 65.53	3.76 hours Standard Deviation 0.01
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	2.17 hours Standard Deviation 0.96	3.06 hours Standard Deviation 1.84	2.36 hours Standard Deviation 0.83	2.53 hours Standard Deviation 1.26	2.62 hours Standard Deviation 0.99	1.77 hours Standard Deviation 0.21
Pharmacokinetic Analysis: Time to Maximum Plasma Concentration (Tmax) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	11.52 hours Standard Deviation 9.85	18.61 hours Standard Deviation 23.73	10.59 hours Standard Deviation 8.32	19.63 hours Standard Deviation 13.53	15.72 hours Standard Deviation 11.79	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	35.2 ug/mL Standard Deviation 2.38	89.9 ug/mL Standard Deviation 15.1	111 ug/mL Standard Deviation 12.4	160 ug/mL Standard Deviation 42.9	267 ug/mL Standard Deviation 48.1	—
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	32.3 ug/mL Standard Deviation 4.01	71.4 ug/mL Standard Deviation 15.7	100 ug/mL Standard Deviation 6.1	142 ug/mL Standard Deviation 28.7	227 ug/mL Standard Deviation 33.7	291 ug/mL Standard Deviation 88.4
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	37 ug/mL Standard Deviation 0.55	90.8 ug/mL Standard Deviation 13.8	118 ug/mL Standard Deviation 16.8	162 ug/mL Standard Deviation 51.9	280 ug/mL Standard Deviation 47.4	—
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	32.3 ug/mL Standard Deviation 1.89	78.8 ug/mL Standard Deviation 23.3	98.6 ug/mL Standard Deviation 7.62	137 ug/mL Standard Deviation 33.7	237 ug/mL Standard Deviation 26.2	279 ug/mL Standard Deviation 61.5

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	1.5 ng/mL Standard Deviation 0.88	4.51 ng/mL Standard Deviation 2.03	4 ng/mL Standard Deviation 1.19	12.8 ng/mL Standard Deviation 11.4	14.6 ng/mL Standard Deviation 3.36	19.4 ng/mL Standard Deviation 1.2
Pharmacokinetic Analysis: Maximum Plasma Concentration (Cmax) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	1.12 ng/mL Standard Deviation 0.25	3.48 ng/mL Standard Deviation 1.18	4.78 ng/mL Standard Deviation 1.35	9.76 ng/mL Standard Deviation 5.13	7.92 ng/mL Standard Deviation 1.4	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in participants with available data in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=3 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=10 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	3.09 ug/mL Standard Deviation 0.57	9.1 ug/mL Standard Deviation 2.16	13.9 ug/mL Standard Deviation 12.9	15.8 ug/mL Standard Deviation 9.27	27.9 ug/mL Standard Deviation 13.6	7.16 ug/mL Standard Deviation 6
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	5.1 ug/mL Standard Deviation 1.87	14.7 ug/mL Standard Deviation 1.68	21 ug/mL Standard Deviation 8.6	28.6 ug/mL Standard Deviation 7.21	52.8 ug/mL Standard Deviation 12	—
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	3.54 ug/mL Standard Deviation 0.84	8.96 ug/mL Standard Deviation 0.36	8.93 ug/mL Standard Deviation 4.9	14.3 ug/mL Standard Deviation 10.1	24.3 ug/mL Standard Deviation 12.6	6.45 ug/mL Standard Deviation 4.82
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for DS-6157a and Total Anti-GPR20 Antibody Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	6.32 ug/mL Standard Deviation 0.87	11.7 ug/mL Standard Deviation 6.05	23 ug/mL Standard Deviation 9.76	30 ug/mL Standard Deviation 10	58.8 ug/mL Standard Deviation 13.2	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in participants with available data in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=3 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=10 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	0.05 ng/mL Standard Deviation 0.01	0.13 ng/mL Standard Deviation 0.03	0.17 ng/mL Standard Deviation 0.10	0.41 ng/mL Standard Deviation 0.35	0.54 ng/mL Standard Deviation 0.28	0.16 ng/mL Standard Deviation 0.20
Pharmacokinetic Analysis: Lowest Concentration Reached After a Single Dose (Ctrough) for MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	0.07 ng/mL Standard Deviation 0.01	0.18 ng/mL Standard Deviation 0.03	0.37 ng/mL Standard Deviation 0.21	1.16 ng/mL Standard Deviation 1.4	0.65 ng/mL Standard Deviation 0.27	—

SECONDARY outcome

Timeframe: Cycle 1, Day 1: Predose, postdose, and 2 hours (hr), 4 hr, 7 hr postdose to Cycle 8, Day 1 predose (each cycle is 21 days)

Population: Pharmacokinetic parameters were assessed in participants with available data in the Pharmacokinetic Analysis Set.

The plasma PK parameters were estimated using standard noncompartmental methods.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=12 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a DS-6157a: Cycle 1	9.05 day Standard Deviation 1.02	8.37 day Standard Deviation 4.91	9.73 day Standard Deviation 3.27	10 day Standard Deviation 4.61	7.58 day Standard Deviation 2.01	2.7 day Standard Deviation 1.52
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a DS-6157a: Cycle 3	9.1 day Standard Deviation 5.38	12.8 day Standard Deviation 4	9.61 day Standard Deviation 5.52	14.7 day Standard Deviation 2.64	11.2 day Standard Deviation 3.95	—
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 1	9.35 day Standard Deviation 2.08	8.49 day Standard Deviation 3.61	9.47 day Standard Deviation 3.45	9.69 day Standard Deviation 4.5	7.94 day Standard Deviation 2.73	11.8 day Standard Deviation 4.72
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a Total anti-GPR20 antibody: Cycle 3	10.7 day Standard Deviation 3.49	10 day Standard Deviation 4.24	13.2 day Standard Deviation 9.28	14.4 day Standard Deviation 1.66	12.7 day Standard Deviation 4.03	—
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 1	5.05 day Standard Deviation 1.23	4.29 day Standard Deviation 1.29	5.35 day Standard Deviation 1.39	6.52 day Standard Deviation 3.59	4.73 day Standard Deviation 0.59	7.27 day Standard Deviation 2.77
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) for DS-6157a, Total Anti-GPR20 Antibody, and MAAA-1181a Following Intravenous Administration of DS-6157a MAAA-1181a: Cycle 3	5.45 day Standard Deviation 1.8	5.67 day Standard Deviation 1.06	6.37 day Standard Deviation 1.32	7.72 day Standard Deviation 1.71	6.67 day Standard Deviation 1.98	—

SECONDARY outcome

Timeframe: Baseline up to long-term follow up (defined as until the start of a new anti-cancer treatment, PD, death, lost to follow up, withdrawal of consent, or at the discretion of the Investigator, whichever occurs first), up to approximately 1 year 10 months.

Population: Best overall response was assessed in the Full Analysis Set.

Based on Response Evaluation Criteria In Solid Tumors guidelines, complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions).

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Best Overall Response Rate Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation) Complete response (CR)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Best Overall Response Rate Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation) Partial response (PR)	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Best Overall Response Rate Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation) Progressive disease (PD)	2 Participants	0 Participants	2 Participants	3 Participants	1 Participants	2 Participants
Best Overall Response Rate Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation) Stable disease (SD)	2 Participants	3 Participants	3 Participants	7 Participants	2 Participants	0 Participants
Best Overall Response Rate Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation) Not evaluable (NE)	0 Participants	1 Participants	0 Participants	2 Participants	3 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to the date of the first documented radiological progression or death due to any cause, whichever occurs first, up to approximately 1 year 10 months

Population: Progression-free survival was assessed in participants with available data (events) in the Full Analysis Set.

Progression-free survival (PFS) is defined as the time from randomization/start of study treatment to the date of event defined as the first documented radiological progression or death due to any cause.

Outcome measures

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 Participants Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=3 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=4 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=7 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=3 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 Participants Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Escalation)	2.6 months Interval 1.2 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.	6.9 months Interval 5.1 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.	10.4 months Interval 0.9 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.	4.2 months Interval 0.8 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.	3.6 months Interval 1.2 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.	1.5 months Interval 1.3 to The maximum 95% confidence interval limit could not be estimated due to insufficient number of events for analysis.

SECONDARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years post-treatment

Population: This outcome measure was not assessed due to early study termination.

Outcome measures

Outcome data not reported

Adverse Events

Dose Escalation: DS-6157a 1.6 mg/kg

Serious events: 1 serious events

Other events: 4 other events

Deaths: 1 deaths

Dose Escalation: DS-6157a 3.2 mg/kg

Serious events: 1 serious events

Other events: 4 other events

Deaths: 0 deaths

Dose Escalation: DS-6157a 4.8 mg/kg

Serious events: 1 serious events

Other events: 5 other events

Deaths: 2 deaths

Dose Escalation: DS-6157a 6.4 mg/kg

Serious events: 2 serious events

Other events: 13 other events

Deaths: 2 deaths

Dose Escalation: DS-6157a 9.6 mg/kg

Serious events: 3 serious events

Other events: 6 other events

Deaths: 1 deaths

Dose Escalation: DS-6157a 12.8 mg/kg

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 participants at risk Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal pain	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Intestinal perforation	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Varices oesophageal	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Pneumonia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Neutrophil count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Platelet count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations White blood cell count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Renal disorder	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.

Other adverse events

Measure	Dose Escalation: DS-6157a 1.6 mg/kg n=4 participants at risk Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous (IV) infusion of DS-6157a 1.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 3.2 mg/kg n=4 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 3.2 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 4.8 mg/kg n=5 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 4.8 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 6.4 mg/kg n=13 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 6.4 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 9.6 mg/kg n=6 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 9.6 mg/kg every 3 weeks.	Dose Escalation: DS-6157a 12.8 mg/kg n=2 participants at risk Participants with advanced GIST who received an IV infusion of DS-6157a 12.8 mg/kg every 3 weeks.
Blood and lymphatic system disorders Anaemia	75.0% 3/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	80.0% 4/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	46.2% 6/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 3/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Cardiac disorders Palpitations	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Cardiac disorders Sinus tachycardia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Cardiac disorders Tachycardia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Endocrine disorders Hyperparathyroidism	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Endocrine disorders Hypothyroidism	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Eye disorders Conjunctival haemorrhage	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Eye disorders Eye disorder	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Eye disorders Lacrimation increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Eye disorders Vitreous floaters	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal distension	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal pain	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Abdominal pain upper	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Anal fissure	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Ascites	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Constipation	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	38.5% 5/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Diarrhoea	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Dry mouth	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Enterocolitis	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Flatulence	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Gastritis	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Gastrooesophageal reflux disease	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Haematemesis	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Intestinal perforation	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Nausea	75.0% 3/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	75.0% 3/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	60.0% 3/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	84.6% 11/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 6/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Varices oesophageal	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Gastrointestinal disorders Vomiting	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	30.8% 4/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Asthenia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Chest discomfort	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Pyrexia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	30.8% 4/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Chills	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Fatigue	75.0% 3/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	60.0% 3/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	46.2% 6/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Influenza like illness	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Infusion site extravasation	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Injection site reaction	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Malaise	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Mucosal inflammation	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
General disorders Oedema peripheral	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	60.0% 3/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Portal hypertension	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Bronchitis	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations COVID-19	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Eye infection	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Herpes zoster	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Pneumonia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Infections and infestations Urinary tract infection	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Injury, poisoning and procedural complications Contusion	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Injury, poisoning and procedural complications Fall	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Injury, poisoning and procedural complications Procedural pain	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Alanine aminotransferase	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Alanine aminotransferase increased	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Aspartate aminotransferase	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Aspartate aminotransferase increased	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Bilirubin conjugated increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood albumin decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood bilirubin increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Muscle fatigue	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood creatinine increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood lactate dehydrogenase increased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Blood potassium decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Electrocardiogram QT prolonged	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Lymphocyte count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Neutrophil count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	38.5% 5/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	66.7% 4/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Platelet count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	30.8% 4/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	83.3% 5/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Protein total decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations Weight decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Investigations White blood cell count decreased	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	83.3% 5/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Decreased appetite	75.0% 3/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	80.0% 4/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	46.2% 6/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	66.7% 4/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Dehydration	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hyperkalaemia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	40.0% 2/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypoglycaemia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hyponatraemia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Arthralgia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Arthritis	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Back pain	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Myalgia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Disturbance in attention	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Dizziness	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	30.8% 4/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Dysarthria	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Dysgeusia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Headache	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	30.8% 4/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Hyperaesthesia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Memory impairment	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Paraesthesia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Nervous system disorders Taste disorder	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Psychiatric disorders Anxiety	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Psychiatric disorders Confusional state	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Psychiatric disorders Delirium	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Psychiatric disorders Insomnia	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Haematuria	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Pollakiuria	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Proteinuria	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Renal disorder	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Reproductive system and breast disorders Pelvic pain	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Cough	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	23.1% 3/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Epistaxis	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Dry skin	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 2/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	60.0% 3/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Hyperhidrosis	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Rash maculo-papular	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	20.0% 1/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	33.3% 2/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Rash papular	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Skin fissures	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	16.7% 1/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Vascular disorders Deep vein thrombosis	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	100.0% 2/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Vascular disorders Haematoma	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	7.7% 1/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Vascular disorders Hot flush	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Vascular disorders Hypertension	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	25.0% 1/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.
Vascular disorders Hypotension	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/4 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/5 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	15.4% 2/13 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	0.00% 0/6 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.	50.0% 1/2 • Adverse event data were collected from baseline up to 30 days after last administration of study drug, up to approximately 1 year 10 months. An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. AEs were graded according to NCI CTCAE Version 5.0. AEs are only reported for the Dose Escalation phase. The Dose Expansion phase was not conducted since the study terminated early.

Additional Information

Contact for Clinical Trial Information

Daiichi Sankyo

Phone: 908-992-6400

Email: CTRinfo@dsi.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place